Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1246 to 1260 of 1422 results for social care

  1. Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

    Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA406

  2. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

    Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA813

  3. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

    Medtech innovation briefing
    Published
    11 March 2016

  4. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued [GID-TA10166]

    Technology appraisal guidance
    Discontinued

  5. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued [GID-TA10631]

    Technology appraisal guidance
    Discontinued

  6. Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

    Discontinued [GID-TA10375]

    Technology appraisal guidance
    Discontinued

  7. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued [GID-TA10709]

    Technology appraisal guidance
    Discontinued

  8. Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538]

    Discontinued [GID-TA10422]

    Technology appraisal guidance
    Discontinued

  9. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued [GID-TA10803]

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued [GID-TA11204]

    Technology appraisal guidance
    Discontinued

  11. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    In development [GID-TA10926] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

    Discontinued [GID-TA10341]

    Technology appraisal guidance
    Discontinued

  13. Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

    Discontinued [GID-TA10923]

    Technology appraisal guidance
    Discontinued

  14. Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

    Discontinued [GID-TA10536]

    Technology appraisal guidance
    Discontinued

  15. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued